Screener
Avalo Therapeutics AVTX Enterprise value
Enterprise value at other companies
Other financials
Where this comes from
Calculated from Avalo Therapeutics’s reported figures.
The source filing: Avalo Therapeutics’s 10-Q, filed August 6, 2026. Open the filing →
- Filed
- Aug 6, 2026, 7:03 AM EDT
- Fiscal quarter
- Q2 FY2026
- Calendar quarter
- Q2 2026
- Accession
- 0001534120-26-000049
FAQ
- What is Avalo Therapeutics's enterprise value?
- Avalo Therapeutics (AVTX) reported enterprise value of $886.04M in Q2 2026.
- How has Avalo Therapeutics's enterprise value changed year-over-year?
- Avalo Therapeutics's enterprise value increased by 7437.1% year-over-year, from $11.76M to $886.04M.
- What is the long-term trend for Avalo Therapeutics's enterprise value?
- Over 5 years (2020 to 2025), Avalo Therapeutics's enterprise value has grown at a 6.1% compound annual growth rate (CAGR), from $232.8M to $313.63M.
- What does enterprise value mean?
- Market capitalization plus total debt minus cash, at the quarter end. The cost to acquire the whole business — what an buyer pays for equity and debt, net of the cash they'd inherit.
Ask your AI about Avalo Therapeutics's enterprise value.
Connect your AI assistant and compare it to peers, right in your chat.
Connect your AI
Claude